Nu Med Plus Stock Fundamentals
| NUMD Stock | USD 0.01 0 10.00% |
Nu Med Plus fundamentals help investors to digest information that contributes to Nu Med's financial success or failures. It also enables traders to predict the movement of NUMD OTC Stock. The fundamental analysis module provides a way to measure Nu Med's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nu Med otc stock.
NUMD |
Nu Med Plus OTC Stock Return On Equity Analysis
Nu Med's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nu Med Return On Equity | -545.23 |
Most of Nu Med's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nu Med Plus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Nu Med Plus has a Return On Equity of -545.2325. This is much higher than that of the Healthcare sector and notably higher than that of the Medical Devices industry. The return on equity for all United States stocks is notably higher than that of the company.
Nu Med Plus Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nu Med's current stock value. Our valuation model uses many indicators to compare Nu Med value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nu Med competition to find correlations between indicators driving Nu Med's intrinsic value. More Info.Nu Med Plus is considered to be number one stock in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nu Med's earnings, one of the primary drivers of an investment's value.NUMD Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nu Med's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Nu Med could also be used in its relative valuation, which is a method of valuing Nu Med by comparing valuation metrics of similar companies.Nu Med is currently under evaluation in return on equity category among its peers.
NUMD Fundamentals
| Return On Equity | -545.23 | |||
| Return On Asset | -6.62 | |||
| Current Valuation | 1.63 M | |||
| Shares Outstanding | 81.35 M | |||
| Shares Owned By Insiders | 61.99 % | |||
| Price To Earning | 19.00 X | |||
| Price To Book | 49.86 X | |||
| EBITDA | (808.68 K) | |||
| Net Income | (830.06 K) | |||
| Cash And Equivalents | 2.54 K | |||
| Total Debt | 2.06 K | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (206.83 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 0.52 | |||
| Market Capitalization | 1.14 M | |||
| Total Asset | 22.16 K | |||
| Retained Earnings | (2.41 M) | |||
| Working Capital | (433.44 K) | |||
| Current Asset | 57.17 K | |||
| Current Liabilities | 490.62 K | |||
| Z Score | 38.4 | |||
| Net Asset | 22.16 K |
About Nu Med Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nu Med Plus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nu Med using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nu Med Plus based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in NUMD OTC Stock
Nu Med financial ratios help investors to determine whether NUMD OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NUMD with respect to the benefits of owning Nu Med security.